Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Raymond A. Farkouh, PhD
Articles
Cost-Effectiveness of Rasagiline Compared With First-Line Early Parkinson Disease Therapies
Raymond A. Farkouh, PhD;Michele R. Wilson, MSPH;Marcy L. Tarrants, PhD, MPA;Jane Castelli-Haley, PhD, MBA;Christophe Armand, MD
June 9th 2012Examination of the cost-effectiveness of rasagiline versus other approved first-line Parkinson disease therapies indicated that rasagiline was either cost saving or cost-effective in all cases.
Read More
Latest Updated Articles
Published: June 12th 2025 | Updated: June 16th 2025
Study: How Individual Carbohydrate Responses Reveal Metabolic Health and Potential Biomarkers
Published: June 10th 2025 | Updated: June 12th 2025
Department of Health and Human Services Reconstitutes ACIP, Removing 17 Sitting Members
Published: June 2nd 2025 | Updated: June 11th 2025
NLA 2025: Managing Omega-3 Therapy With Statins, PCSK9 Inhibitors for Cardiovascular Care
Published: June 3rd 2025 | Updated: June 11th 2025
ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment Landscape
Published: May 30th 2025 | Updated: June 5th 2025
Emerging Data: Impacts of ROCKstar and AGAVE-201
Published: April 18th 2025 | Updated: April 21st 2025
Measles Cases Climb to 800 in United States as Outbreak Spreads Across Borders
